Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation　― The Fushimi AF Registry ―

PCI) in patients requiring OAC, triple therapy (OAC plus dual APD) was inferior to double therapy (OAC plus single APD) in a randomized trial in patients receiving warfarin. n AF patients receiving a combination of non-vitamin K antagonist OAC (NOAC) and single APD, bleeding risk was reduced compared with conventional triple therapy (warfarin plus dual APD). 8,9 Beyond 1 year, current European guidelines recommend OAC monotherapy for AF patients with stable vascular disease. 10 There is no evidence, however, based on randomized controlled trials regarding OAC S troke prevention is central to the management of atrial fibrillation (AF), and oral anticoagulants (OAC) are recommended in guidelines to reduce the risk of ischemic stroke and mortality. 1 Many AF patients have concomitant atherosclerotic disease such as coronary artery disease (CAD) and peripheral artery disease (PAD). 2,3 Therefore, the combination of OAC and antiplatelet drugs (APD) is often prescribed, although this is likely to increase the risk of bleeding. 4-6